The menin inhibitor VTP-50469 was evaluated against a total of 16 PDX models (7 solid tumor, 9 ALL) administered twice daily for an intended 28 days at a dose of 120 mg/kg (Krivtsov et al., 2019; Kurmasheva et al., 2020). The gene discussed is MEN1; the disease is acute lymphoblastic leukemia.